Abstract
BACKGROUND/AIMS: Pancreatic cancer is the 5(th) leading cause of cancer death in Korea and its incidence is increasing. At present, surgical resection offers the best chance of cure. However, most of pancreatic cancers are already unresectable at initial diagnosis. Thus, the majority of patients depend on chemotherapy, radiotherapy, or supportive care. We investigated the effect of treatment modalities on the survival in pancreatic cancer. METHODS: Between September 1994 and May 2003, one hundred and fifty four patients with pancreatic cancer were treated by surgery, radiotherapy, chemotherapy or conservative management. The clinical datas were analyzed retrospectively for survival according to stage and treatment modality. RESULTS: Overall median survival time was 5.7 months and 1 year survival rate was 18.3%. In patients with stage I to III disease, the median survival time was 13.9 months in surgery group, 10.2 months in radiation group, and 6.1 months in supportive care group (p%lt;0.01). Survival rate according to treatment modality was significantly different among groups. In patients with stage IV disease, the median survival time was 6.1 months in radiation therapy group, 7.1 months in chemotherapy group, and 2.7 months in supportive care group. Overall survival was significantly higher in treatment groups than in supportive care group (p<0.01), but there was no difference in survival between chemotherapy group and radiotherapy group. CONCLUSIONS: In patients with stage I to III pancreatic cancer, surgery can improve median survival. In patients with stage IV, either chemotherapy or radiotherapy can prolong survival compared to supportive care. These results suggest that more active treatment of pancreatic cancer even in advanced stage will be needed to prolong the survival.
| Original language | English |
|---|---|
| Pages (from-to) | 120-128 |
| Number of pages | 9 |
| Journal | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi |
| Volume | 46 |
| Issue number | 2 |
| Publication status | Published - 2005 Jan 1 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Survival analysis according to treatment modality in pancreatic cancer patient. / Jung, Sung Woo; Park, Jae Youn; Kim, Yong Sik; Jeen, Yoon Tae; Lee, Hong Sik; Chun, Hoon-Jai; Um, Soon-Ho; Lee, Sang Woo; Choi, Jai Hyun; Kim, Chang Duck; Ryu, Ho Sang; Hyun, Jin Hai.
In: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, Vol. 46, No. 2, 01.01.2005, p. 120-128.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Survival analysis according to treatment modality in pancreatic cancer patient
AU - Jung, Sung Woo
AU - Park, Jae Youn
AU - Kim, Yong Sik
AU - Jeen, Yoon Tae
AU - Lee, Hong Sik
AU - Chun, Hoon-Jai
AU - Um, Soon-Ho
AU - Lee, Sang Woo
AU - Choi, Jai Hyun
AU - Kim, Chang Duck
AU - Ryu, Ho Sang
AU - Hyun, Jin Hai
PY - 2005/1/1
Y1 - 2005/1/1
N2 - BACKGROUND/AIMS: Pancreatic cancer is the 5(th) leading cause of cancer death in Korea and its incidence is increasing. At present, surgical resection offers the best chance of cure. However, most of pancreatic cancers are already unresectable at initial diagnosis. Thus, the majority of patients depend on chemotherapy, radiotherapy, or supportive care. We investigated the effect of treatment modalities on the survival in pancreatic cancer. METHODS: Between September 1994 and May 2003, one hundred and fifty four patients with pancreatic cancer were treated by surgery, radiotherapy, chemotherapy or conservative management. The clinical datas were analyzed retrospectively for survival according to stage and treatment modality. RESULTS: Overall median survival time was 5.7 months and 1 year survival rate was 18.3%. In patients with stage I to III disease, the median survival time was 13.9 months in surgery group, 10.2 months in radiation group, and 6.1 months in supportive care group (p%lt;0.01). Survival rate according to treatment modality was significantly different among groups. In patients with stage IV disease, the median survival time was 6.1 months in radiation therapy group, 7.1 months in chemotherapy group, and 2.7 months in supportive care group. Overall survival was significantly higher in treatment groups than in supportive care group (p<0.01), but there was no difference in survival between chemotherapy group and radiotherapy group. CONCLUSIONS: In patients with stage I to III pancreatic cancer, surgery can improve median survival. In patients with stage IV, either chemotherapy or radiotherapy can prolong survival compared to supportive care. These results suggest that more active treatment of pancreatic cancer even in advanced stage will be needed to prolong the survival.
AB - BACKGROUND/AIMS: Pancreatic cancer is the 5(th) leading cause of cancer death in Korea and its incidence is increasing. At present, surgical resection offers the best chance of cure. However, most of pancreatic cancers are already unresectable at initial diagnosis. Thus, the majority of patients depend on chemotherapy, radiotherapy, or supportive care. We investigated the effect of treatment modalities on the survival in pancreatic cancer. METHODS: Between September 1994 and May 2003, one hundred and fifty four patients with pancreatic cancer were treated by surgery, radiotherapy, chemotherapy or conservative management. The clinical datas were analyzed retrospectively for survival according to stage and treatment modality. RESULTS: Overall median survival time was 5.7 months and 1 year survival rate was 18.3%. In patients with stage I to III disease, the median survival time was 13.9 months in surgery group, 10.2 months in radiation group, and 6.1 months in supportive care group (p%lt;0.01). Survival rate according to treatment modality was significantly different among groups. In patients with stage IV disease, the median survival time was 6.1 months in radiation therapy group, 7.1 months in chemotherapy group, and 2.7 months in supportive care group. Overall survival was significantly higher in treatment groups than in supportive care group (p<0.01), but there was no difference in survival between chemotherapy group and radiotherapy group. CONCLUSIONS: In patients with stage I to III pancreatic cancer, surgery can improve median survival. In patients with stage IV, either chemotherapy or radiotherapy can prolong survival compared to supportive care. These results suggest that more active treatment of pancreatic cancer even in advanced stage will be needed to prolong the survival.
UR - http://www.scopus.com/inward/record.url?scp=33644892555&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33644892555&partnerID=8YFLogxK
M3 - Article
VL - 46
SP - 120
EP - 128
JO - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
JF - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
SN - 1598-9992
IS - 2
ER -